On October 23, 2019 The Board of Directors of McKesson Corporation (NYSE:MCK) reported a regular dividend of 41 cents per share of common stock (Press release, McKesson, OCT 23, 2019, View Source [SID1234542452]). The dividend will be payable on January 2, 2020, to stockholders of record on December 2, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 22, 2019 Incyte Corporation (Nasdaq:INCY) reported that it will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am (MST) / 10:35 am (EST) in Scottsdale, Arizona (Press release, Incyte, OCT 22, 2019, View Source [SID1234542403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

On October 22, 2019 Systems Oncology, LLC ("SO") and The Pritzker Organization, LLC ("TPO") reported that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round (Press release, Systems Oncology, OCT 22, 2019, View Source [SID1234542419]). The funding will be used to invest in both discovery research and pre-clinical development to evolve SO’s rapidly expanding pipeline of innovative cancer therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Systems Oncology leverages big data and AI to discover novel scientific insights into cancer biology. These therapeutic insights are then applied to build therapeutic programs. Specifically, SO’s ExpansiveAI discovery engine allows scientists to integrate and translate big data from hundreds of scientific sources into intelligently linked scientific knowledge, making it possible to uncover truly unique therapeutic opportunities. This cognitive computing platform integrates and connects multiple different kinds of data into multidimensional models, which in turn allows for unprecedented scale and efficiency in applying machine learning to mine trillions of biomedical relationships. This engine enables SO to explore a massive universe of therapeutic opportunities many orders of magnitude more expansive than the human mind can imagine.

"We are honored by the investment from The Pritzker Organization and look forward to them joining us with a seat on our Board of Directors," said Dr. Spyro Mousses, CEO of Systems Oncology. "TPO’s investment is a prestigious recognition for the potential SO has to transform drug discovery and development with AI. They bring a wealth of experience investing in and growing companies and will help us continue to grow for years to come and fulfill our commitment to bring forward breakthrough oncology therapeutics for unmet patient needs."

"We are very excited about the potential for Systems Oncology’s combination of leading-edge AI and outstanding clinical expertise to produce novel cancer therapies," said Joseph Gleberman, TPO Managing Director.

On October 22, 2019 Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, reported that data from the ongoing clinical trial of its lead product candidate INT230-6 was selected for a podium presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 34th Annual Meeting, taking place November 6-10, 2019, in National Harbor, MD (Press release, Intensity Therapeutics, OCT 22, 2019, View Source [SID1234542404]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation are as follows:

Title: Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types

Abstract Number: O31

Date/Time: Saturday, November 9, 2019, 3:45-4:00 p.m. ET

Session: Concurrent Session 309: Single Agent Phase 1 Clinical Trials

Location: Prince George’s Exhibition Hall C

Presenter: Jacob Thomas, MD, Assistant Professor of Clinical Medicine, University of Southern California

To view the schedule for SITC (Free SITC Whitepaper) 2019, please visit: View Source

About INT230-6

INT230-6, Intensity’s lead product candidate designed for direct intratumoral injection, is comprised of two proven, potent anti-cancer agents and a penetration enhancer molecule that helps disperse the drugs throughout tumors and diffuse into cancer cells. INT230-6 is being evaluated in a Phase 1/2 clinical study (NCT03058289) in patients with various advanced solid tumors. In preclinical studies, INT230-6 eradicated tumors by a combination of direct tumor kill and recruitment of dendritic cells to the tumor micro-environment that induced anti-cancer T-cell activation. Treatment with INT230-6 in in vivo models of severe cancer resulted in substantial improvement in overall survival compared to standard therapies. Further, INT230-6 provided complete responder animals with long-term and durable protection from multiple re-inoculations of the initial cancer. In mouse models, INT230-6 has shown strong synergy with checkpoint blockage, including anti-PD-1 and anti-CTLA4 antibodies. INT230-6 was discovered from Intensity’s DfuseRxSM platform.

On October 22, 2019 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that it will release its financial results for third quarter 2019 after the close of trading on Wednesday, November 6, 2019 (Press release, Quanterix, OCT 22, 2019, View Source [SID1234542420]). Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 5798993. A live webcast will also be available at: View Source The webcast will be available on the Company’s website, View Source, for one year following completion of the call.